Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
Veterans and AL Amyloidosis
AL Amyloidosis and Agent Orange
Veterans who develop AL amyloidosis and were exposed to Agent Orange or other herbicides during military service do not have to prove a connection between their disease and service to be eligible to receive VA health care and disability compensation.
About AL amyloidosis
AL amyloidosis is a rare disease caused when amyloid proteins are abnormally deposited in tissues or organs. Primary (AL) amyloidosis is the most common form. AL amyloidosis is not a cancer, but it can occur because of some cancers.
myBinderRelated Content
-
Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (Daratumumab and Hyaluronidase-fihj) for...The Janssen Pharmaceutical Companies of ...
-
MAGE Genes: Prognostic Indicators in AL Amyloidosis PatientsA high frequency of MAGE-CT (cancer te...
-
San Diego — Amyloidosis Support Groups Meeting — LIVE — Saturday, April 27, 2024When: Saturday, April 27, 2024 AL wi...
-
Daratumumab-Based Therapies in Patients With AL AmyloidosisBackground: Treatment options for patie...
-
Depression and Anxiety in Patients With AL Amyloidosis as Assessed by the SF-36 QuestionnaireBackground: Our study examines depressi...
-
Alexion Pharmaceuticals Partners With Caelum Biosciences to Tackle Light Chain AmyloidosisAlexion Pharmaceuticals (ALXN) has been ...
-
New and Developing Therapies for AL AmyloidosisSystemic light-chain (AL) amyloidosis is...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
